

SHIKARI®

Corporate & Product Overview

ELISA kits for research measurement of biological-drug and trough levels, anti-drug antibodies, and selected neutralising-antibody formats.

134

SHIKARI PRODUCTS

45

BIOLOGICAL DRUGS

2002

COMPANY FOUNDED

2008

SHIKARI SINCE

A focused research portfolio

The SHIKARI® portfolio comprises 134 research-use products covering 45 biological drugs. The available formats include quantitative drug- and trough-level assays, qualitative and quantitative anti-drug-antibody assays, free/total antibody formats, drug-specific mAb-based assays and selected qualitative neutralising-antibody assays.

Research-use status

All products listed in this overview are for Research Use Only. Exact intended use, technical specifications and availability are governed by the current product documentation.

Company roles and assay formats

Matrix Biotek coordinates EU commercial, marketing and scientific support from Barcelona. The SHIKARI® portfolio is developed and manufactured by Matriks Biyoteknoloji Ltd. Şti. in Ankara.

EU headquarters and commercial hub

Matrix Biotek SL
Commercial, marketing, distribution and fulfilment hub for the European Union.
Talent Garden - 22@, Carrer de Ramon Turró 169, 08005 Barcelona, Spain

Development, manufacturing and R&D

Matriks Biyoteknoloji Ltd. Şti.
SHIKARI® assay development and manufacture at Hacettepe Teknokent, Ankara, Türkiye.
Manufacturing under an ISO 13485 quality-management system.

Research assay formats represented in the portfolio

01 Drug- and trough-level assays

Quantitative determination of the named biological drug, including in trough samples collected before the next dose.

02 Drug-specific mAb-based assays

Quantitative drug- and trough-level assays using a drug-specific monoclonal-antibody format.

03 Qualitative ADA screening

Qualitative detection of antibodies to the named biological drug.

04 Quantitative ADA assays

Quantitative anti-drug-antibody assays; selected products include confirmation reagent.

05 Free/total ADA formats

Semi-quantitative assessment of free and total anti-drug antibodies for selected drugs.

06 T-CAP NAb assays

Qualitative detection of free neutralising anti-drug antibodies for selected drugs.

Use and interpretation: These assays are research tools. This overview does not provide diagnostic claims, treatment thresholds, dosing instructions or patient-management recommendations. Consult the current IFU and validation documentation for the exact intended research use and specifications of each kit.

Inflammatory and autoimmune biologics

32 products in this portfolio section

BIOLOGICAL DRUG / BRAND	ASSAY PURPOSE	ASSAY RANGE / LoD*	REF CODE
Adalimumab (Humira®)	Drug / trough level - quantitative	0.3–10 µg/ml	ADA-FD-HUM
	Drug / trough level, mAb-based - quantitative	0.2–6 µg/ml	ADA-SPEC-ADA
	Anti-drug antibody - qualitative	Qualitative	ADA-QLS-HUM
	Anti-drug antibody, free/total - semi-quantitative	Qualitative	ADA-QNFT-HUM
	Anti-drug antibody - quantitative	0.1–1.6 µg/ml	ADA-QNS-HUM
	Neutralising antibody - qualitative	Qualitative	ADA-TCAP-NAb-HUM
Infliximab (Remicade®)	Drug / trough level - quantitative	2–60 µg/ml	INF-FD-REMI
	Drug / trough level, mAb-based - quantitative	0.2–20 µg/ml	INF-SPEC-INF
	Anti-drug antibody - qualitative	Qualitative	INF-QLS-REMI
	Anti-drug antibody - quantitative	0.1–3 µg/ml	INF-QNS-REMI
	Anti-drug antibody, free/total - semi-quantitative	Qualitative	INF-QNFT-REMI
	Neutralising antibody - qualitative	Qualitative	INF-TCAP-NAb-REMI
Infliximab (Remsima® / Inflectra®)	Drug / trough level - quantitative	2–60 µg/ml	INF-FD-REMS
	Anti-drug antibody - qualitative	Qualitative	INF-QLS-REMS
	Anti-drug antibody - quantitative	0.1–3 µg/ml	INF-QNS-REMS
	Anti-drug antibody, free/total - semi-quantitative	Qualitative	INF-QNFT-REMS
Vedolizumab (Entyvio®)	Drug / trough level - quantitative	6–200 µg/ml	VED-FD-ENT
	Drug / trough level, mAb-based - quantitative	6–200 µg/ml	VED-SPEC-VED
	Anti-drug antibody - quantitative	0.1–1.6 µg/ml	VED-QNS-ENT
	Anti-drug antibody - qualitative	Qualitative	VED-QLS-ENT
	Neutralising antibody - qualitative	Qualitative	VED-TCAP-NAb-ENT
Certolizumab (Cimzia®)	Drug / trough level - quantitative	6–200 µg/ml	CER-FD-CIM
	Anti-drug antibody - quantitative	1–16 µg/ml	CER-QNS-CIM
	Neutralising antibody - qualitative	Qualitative	CER-TCAP-NAb-CIM
Golimumab (Simponi®)	Drug / trough level - quantitative	1–30 µg/ml	GOL-FD-SIM
	Anti-drug antibody - qualitative	Qualitative	GOL-QLS-SIM
	Anti-drug antibody - quantitative	3.21–50 µg/ml	GOL-QNS-SIM
Natalizumab (Tysabri®)	Drug / trough level - quantitative	60–2000 µg/ml	NAT-FD-TYS
	Anti-drug antibody - qualitative	Qualitative	NAT-QLS-TYS
	Anti-drug antibody - quantitative	0.312–5 µg/ml	NAT-QNS-TYS
Etanercept (Enbrel®)	Drug / trough level - quantitative	10–300 µg/ml	ETA-FD-ENB
	Anti-drug antibody - qualitative	Qualitative	ETA-QLS-ENB

* Values reproduce the original product assay ranges or limits of detection; they are not clinical treatment targets. Reference brands identify the biological drug only. All third-party marks belong to their respective owners.

Immuno-oncology and checkpoint inhibitors

18 products in this portfolio section

BIOLOGICAL DRUG / BRAND	ASSAY PURPOSE	ASSAY RANGE / LoD*	REF CODE
Pembrolizumab (Keytruda®)	Drug / trough level - quantitative	3-100 µg/ml	PEM-FD-KEY
	Anti-drug antibody - qualitative	Qualitative	PEM-QLS-KEY
	Anti-drug antibody - quantitative	0.1-1.6 µg/ml	PEM-QNS-KEY
	Neutralising antibody - qualitative	Qualitative	PEM-TCAP-NAb-KEY
Nivolumab (Opdivo®)	Drug / trough level - quantitative	3-100 µg/ml	NIV-FD-OPD
	Drug / trough level, mAb-based - quantitative	10 ng/mL (LoD)	NIV-SPEC-NIV
	Anti-drug antibody - qualitative	Qualitative	NIV-QLS-OPD
	Anti-drug antibody - quantitative	3.12-50 µg/ml	NIV-QNS-OPD
	Neutralising antibody - qualitative	Qualitative	NIV-TCAP-NAb-OPD
Atezolizumab (Tecentriq®)	Drug / trough level - quantitative	10-300 µg/ml	ATE-FD-TEC
	Anti-drug antibody - qualitative	Qualitative	ATE-QLS-TEC
Ipilimumab (Yervoy®)	Drug / trough level - quantitative	3-90 µg/ml	IPI-FD-YER
	Anti-drug antibody - qualitative	Qualitative	IPI-QLS-YER
	Anti-drug antibody - quantitative	6.25-116 µg/ml	IPI-QNS-YER
Durvalumab (Imfinzi®)	Drug / trough level - quantitative	10-300 µg/ml	DUR-FD-IMF
	Anti-drug antibody - qualitative	Qualitative	DUR-QLS-IMF
Avelumab (Bavencio®)	Drug / trough level - quantitative	10-300 µg/ml	AVE-FD-BAV
	Anti-drug antibody - qualitative	Qualitative	AVE-QLS-BAV

* Values reproduce the original product assay ranges or limits of detection; they are not clinical treatment targets. Reference brands identify the biological drug only. All third-party marks belong to their respective owners.

Targeted oncology and angiogenesis

26 products in this portfolio section

BIOLOGICAL DRUG / BRAND	ASSAY PURPOSE	ASSAY RANGE / LoD*	REF CODE
Trastuzumab (Herceptin®)	Drug / trough level - quantitative	10-300 µg/ml	TRA-FD-HH
	Drug / trough level, mAb-based - quantitative	3-300 µg/ml	TRA-SPEC-TRA
	Anti-drug antibody - qualitative	Qualitative	TRA-QLS-HH
	Anti-drug antibody - quantitative	0.1-1.6 µg/ml	TRA-QNS-HH
	Neutralising antibody - qualitative	Qualitative	TRA-TCAP-NAb-HH
Rituximab (MabThera® / Rituxan®)	Drug / trough level - quantitative	3-100 µg/ml	RIT-FD-RM
	Anti-drug antibody - qualitative	Qualitative	RIT-QLS-RM
	Anti-drug antibody - quantitative	0.1-1.6 µg/ml	RIT-QNS-RM
	Neutralising antibody - qualitative	Qualitative	RIT-TCAP-NAb-RM
Bevacizumab (Avastin®)	Drug / trough level - quantitative	3-100 µg/ml	BEV-FD-AA
	Anti-drug antibody - qualitative	Qualitative	BEV-QLS-AA
	Anti-drug antibody - quantitative	0.1-1.6 µg/ml	BEV-QNS-AA
	Neutralising antibody - qualitative	Qualitative	BEV-TCAP-NAb-AA
Pertuzumab (Perjeta®)	Drug / trough level - quantitative	15-1500 µg/ml	PER-FD-PER
	Anti-drug antibody - qualitative	Qualitative	PER-QLS-PER
	Drug / trough level, mAb-based - quantitative	5-500 µg/ml	PER-SPEC-PER
Cetuximab (Erbix®)	Drug / trough level - quantitative	10-300 µg/ml	CET-FD-ERB
	Anti-drug antibody - qualitative	Qualitative	CET-QLS-ERB
	Anti-drug antibody - quantitative	0.31-5 µg/ml	CET-QNS-ERB
Daratumumab (Darzalex®)	Drug / trough level - quantitative	60-2000 µg/ml	DAR-FD-DAR
	Anti-drug antibody - qualitative	Qualitative	DAR-QLS-DAR
Ramucirumab (Cyramza®)	Drug / trough level - quantitative	20-600 µg/ml	RAM-FD-CYR
	Anti-drug antibody - qualitative	Qualitative	RAM-QLS-CYR
Ranibizumab (Lucentis®)	Drug level - quantitative (aqueous humour)	10-300 µg/ml	RAN-FD-LUC
Ocrelizumab (Ocrevus®)	Drug / trough level - quantitative	1.56 ng/mL	OCR-FD-OCR
	Anti-drug antibody - quantitative	0.5 µg/mL (LoD)	OCR-QNS-OCR

* Values reproduce the original product assay ranges or limits of detection; they are not clinical treatment targets. Reference brands identify the biological drug only. All third-party marks belong to their respective owners.

Interleukin and cytokine pathways

31 products in this portfolio section

BIOLOGICAL DRUG / BRAND	ASSAY PURPOSE	ASSAY RANGE / LoD*	REF CODE
Guselkumab (Tremfya®)	Drug / trough level - quantitative	1–30 µg/ml	GUS-FD-TRE
	Drug / trough level, mAb-based - quantitative	0.3–10 µg/ml	GUS-SPEC-GUS
	Anti-drug antibody - quantitative	0.2–3.2 µg/ml	GUS-QNS-TRE
Risankizumab (Skyrizi®)	Drug / trough level - quantitative	0.1–30 µg/ml	RIS-FD-SKY
	Drug / trough level, mAb-based - quantitative	0.3–10 µg/ml	RIS-SPEC-RIS
	Anti-drug antibody - qualitative	Qualitative	RIS-QLS-SKY
Ustekinumab (Stelara®)	Anti-drug antibody - quantitative	0.2–3.2 µg/ml	RIS-QNS-SKY
	Drug / trough level - quantitative	0.6–200 µg/ml	UST-FD-STE
	Drug / trough level, mAb-based - quantitative	0.6–60 µg/ml	UST-SPEC-UST
	Anti-drug antibody - qualitative	Qualitative	UST-QLS-STE
	Anti-drug antibody - quantitative	0.1–1.6 µg/ml	UST-QNS-STE
	Neutralising antibody - qualitative	Qualitative	UST-TCAP-NAb-STE
Mirikizumab (Omvoh®)	Drug / trough level - quantitative	0.6–600 µg/ml	MIR-FD-OMV
	Anti-drug antibody - qualitative	Qualitative	MIR-QLS-OMV
Tocilizumab (Actemra®)	Drug / trough level - quantitative	10–300 µg/ml	TOC-FD-ACT
	Anti-drug antibody - qualitative	Qualitative	TOC-QLS-ACT
	Anti-drug antibody - quantitative	10–160 µg/ml	TOC-QNS-ACT
Secukinumab (Cosentyx®)	Drug / trough level - quantitative	6.25–100 µg/ml	SEC-FD-VER
	Anti-drug antibody - qualitative	Qualitative	SEC-QLS-VER
Ixekizumab (Taltz®)	Drug / trough level - quantitative	2–16 µg/ml	IXE-FD-TAL
	Anti-drug antibody - qualitative	Qualitative	IXE-QLS-TAL
Mepolizumab (Nucala®)	Drug / trough level - quantitative	3–100 µg/ml	MEP-FD-NUC
	Anti-drug antibody - qualitative	Qualitative	MEP-QLS-NUC
Benralizumab (Fasenra®)	Drug / trough level - quantitative	1–30 µg/ml	BEN-FD-FAS
	Anti-drug antibody - qualitative	Qualitative	BEN-QLS-FAS
Canakinumab (Ilaris®)	Drug / trough level - quantitative	3–100 µg/ml	CAN-FD-ILA
	Anti-drug antibody - qualitative	Qualitative	CAN-QLS-ILA
	Anti-drug antibody - quantitative	0.31–5 µg/ml	CAN-QNS-ILA
Omaliuzumab (Xolair®)	Drug / trough level - quantitative	10 ng/mL (LoD)	OMA-FD-XOL
	Anti-drug antibody - qualitative	Qualitative	OMA-QLS-XOL
	Anti-drug antibody - quantitative	7.5 ng/mL (LoD)	OMA-QNS-XOL

* Values reproduce the original product assay ranges or limits of detection; they are not clinical treatment targets. Reference brands identify the biological drug only. All third-party marks belong to their respective owners.

Complement, metabolic and other biologics

27 products in this portfolio section

BIOLOGICAL DRUG / BRAND	ASSAY PURPOSE	ASSAY RANGE / LoD*	REF CODE
Eculizumab (Soliris®)	Drug / trough level, mAb-based - quantitative	40–1200 µg/ml	ECU-SPEC-ECU
	Anti-drug antibody - qualitative	Qualitative	ECU-QLS-SOL
	Anti-drug antibody - quantitative	0.2–3.2 µg/ml	ECU-QNS-SOL
	Neutralising antibody - qualitative	Qualitative	ECU-TCAP-NAb-SOL
Denosumab (Prolia® / Xgeva®)	Drug / trough level - quantitative	5–80 µg/ml	DEN-FD-PRO
	Anti-drug antibody - qualitative	Qualitative	DEN-QLS-PRO
	Anti-drug antibody - quantitative	0.31–5 µg/ml	DEN-QNS-PRO
Abatacept (Orencia®)	Drug / trough level - quantitative	3–100 µg/ml	ABA-FD-ORE
	Anti-drug antibody - qualitative	Qualitative	ABA-QLS-ORE
	Anti-drug antibody - quantitative	0.6–100 µg/ml	ABA-QNS-ORE
Dupilumab (Dupixent®)	Drug / trough level - quantitative	5–80 µg/ml	DUP-FD-DUP
	Anti-drug antibody - qualitative	Qualitative	DUP-QLS-DUP
	Anti-drug antibody - quantitative	10 ng/ml (LoD)	DUP-QNS-DUP
Ravulizumab (Ultomiris®)	Drug / trough level, mAb-based - quantitative	40–1200 µg/ml	RAV-FD-ULT
	Anti-drug antibody - quantitative	0.2–3.2 µg/ml	RAV-QNS-ULT
Aflibercept (Eylea®)	Drug / trough level - quantitative	3–100 µg/ml	AFL-FD-EYL
	Anti-drug antibody - qualitative	Qualitative	AFL-QLS-EYL
	Anti-drug antibody - quantitative	0.03–3 µg/ml	AFL-QNS-EYL
Semaglutide (Ozempic® / Wegovy®)	Anti-drug antibody - quantitative	2.5–75 ng/ml	SEM-QNS-OZE
Enfortumab (Padcev®)	Drug / trough level - quantitative	0.3–10 µg/ml	ENF-FD-PAD
	Anti-drug antibody - qualitative	Qualitative	ENF-QLS-PAD
Evolocumab (Repatha®)	Drug / trough level - quantitative	6.25–100 µg/ml	EVO-FD-REP
	Anti-drug antibody - qualitative	Qualitative	EVO-QLS-REP
Palivizumab (Synagis®)	Drug / trough level - quantitative	3 ng/mL (LoD)	PAL-FD-SYN
	Anti-drug antibody - qualitative	Qualitative	PAL-QLS-SYN
	Anti-drug antibody - quantitative	18.75 ng/mL (LoD)	PAL-QNS-SYN
Filgrastim (Neupogen®)	Anti-drug antibody - quantitative	31.3–500 ng/ml	FIL-QNS-FRA

* Values reproduce the original product assay ranges or limits of detection; they are not clinical treatment targets. Reference brands identify the biological drug only. All third-party marks belong to their respective owners.

Research, technical information & contact

Matrix Biotek welcomes scientific enquiries, research collaborations, distributor discussions and requests for current technical documentation. The Barcelona team coordinates EU scientific support and commercial follow-up.

Request the right information

- 1** Identify the biological drug and the research question.
- 2** Identify the relevant drug/trough-level, ADA, free/total ADA or neutralising-antibody format.
- 3** Request the current IFU, validation material, SDS and quotation.

Current research and collaboration interests

- Biological-drug and trough-level research with anti-drug-antibody assay development
- Assay development for emerging biologics and biosimilar research
- Functional antibody and neutralising-antibody research formats
- Fungal biomarkers, inflammatory pathways and collaborative R&D; projects

Matrix Biotek

Talent Garden - 22@

Carrer de Ramon Turró 169, 08005 Barcelona, Spain

General & technical

info@matrixbiotek.com

Orders & quotations

orders@matrixbiotek.com

Portfolio note: Product availability, specifications, sample requirements and assay times may change. Current product IFUs and validation documents take precedence over this summary. This overview makes no diagnostic, treatment or clinical-performance claim.